Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 19Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Myelodysplastic Syndromes 100Leukemia, Myeloid, Acute 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Myeloproliferative Disorders 40Leukemia, Myelogenous, Chronic, BCR-ABL Positive 37Leukemia, Myelomonocytic, Chronic 32Primary Myelofibrosis 30Lymphoma, Non-Hodgkin 30Polycythemia Vera 19Lymphoma 15Leukemia 15Hematologic Neoplasms 15Leukemia, Biphenotypic, Acute 14Thrombocythemia, Essential 13Multiple Myeloma 11Hodgkin Disease 11Histiocytosis, Langerhans-Cell 11Neoplasms 10Leukemia, Myeloid, Chronic-Phase 10Leukemia, Lymphocytic, Chronic, B-Cell 10Rhabdoid Tumor 9Neuroblastoma 9Medulloblastoma 9Glioma 9Ependymoma 9Anemia, Refractory, with Excess of Blasts 9Wilms Tumor 8Sarcoma 8Rhabdomyosarcoma 8Osteosarcoma 8

Interventions

nilotinib 2asciminib 2bosutinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Philadelphia Chromosome × Myeloid × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡